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Abstract
Background: Helminth infections are proposed to have immunomodulatory activities affecting health outcomes either
detrimentally or beneficially. We evaluated the effects of albendazole treatment, every three months for 21 months, on STH,
malarial parasitemia and allergy.
Methods and Findings: A household-based cluster-randomized, double-blind, placebo-controlled trial was conducted in an
area in Indonesia endemic for STH. Using computer-aided block randomization, 481 households (2022 subjects) and 473
households (1982 subjects) were assigned to receive placebo and albendazole, respectively, every three months. The
treatment code was concealed from trial investigators and participants. Malarial parasitemia and malaria-like symptoms
were assessed in participants older than four years of age while skin prick test (SPT) to allergens as well as reported
symptoms of allergy in children aged 5–15 years. The general impact of treatment on STH prevalence and body mass index
(BMI) was evaluated. Primary outcomes were prevalence of malarial parasitemia and SPT to any allergen. Analysis was by
intention to treat. At 9 and 21 months post-treatment 80.8% and 80.1% of the study subjects were retained, respectively.
The intensive treatment regiment resulted in a reduction in the prevalence of STH by 48% in albendazole and 9% in placebo
group. Albendazole treatment led to a transient increase in malarial parasitemia at 6 months post treatment (OR 4.16(1.35–
12.80)) and no statistically significant increase in SPT reactivity (OR 1.18(0.74–1.86) at 9 months or 1.37 (0.93–2.01) 21
months). No effect of anthelminthic treatment was found on BMI, reported malaria-like- and allergy symptoms. No adverse
effects were reported.
Conclusions: The study indicates that intensive community treatment of 3 monthly albendazole administration for 21 months
over two years leads to a reduction in STH. This degree of reduction appears safe without any increased risk of malaria or allergies.
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Introduction
Soil transmitted helminths (STH) (hookworms, Ascaris lumbri-
coides and Trichuris trichiura) establish chronic infections in a large
proportion of the world population.[1] Major intervention
programs using mass drug administration (MDA) to control
STH have been launched.[2] However, STH infections seem to
persist in the targeted populations raising concern over the
development of drug resistance.[3] It is therefore important to
conduct well-designed studies that allow evidence-based decisions
to be made to maximize effective STH control toward elimination.
While there is no doubt that STH are associated with
morbidities in billions of people worldwide, there is also increasing
awareness that helminth infections might, like bacterial commen-
sals, play an important role in shaping human health.[4]
Helminths may contribute to immunologic and physiologic
homeostasis. The immune system is thought to have evolved to
operate optimally in the face of helminth-induced immune
regulation, and that any disturbance of this long evolutionary
co-existence between humans and helminth parasites might be
associated with the emergence of pathological conditions[5]
possibly involving outcomes of exposure to other pathogens or
the development of inflammatory diseases.
In many parts of the world helminths and malarial parasites are
co-endemic raising the question of what impact helminth
infections may have on the plasmodial parasites that cause
malaria. The results have been conflicting in this regard. In some
studies a positive association has been reported between helminths
and malarial parasitemia while in others, this has been refuted or
in yet others a negative association has been shown between
helminths and the severity of the clinical outcomes of malaria
(reviewed by Nacher).[6]
An increase in the prevalence of allergies has been reported
worldwide, in particular in the urban areas of low- to middle-
income countries.[7] Although majority of cross-sectional studies
have reported inverse associations between helminth infections
and allergies[8,9], two randomized trials with albendazole, have
shown conflicting results. One in Ecuador, based on school
randomization, reported no change in either SPT reactivity to
allergens or allergic symptoms after one year of albendazole
treatment[10] while another in Vietnam, in which the random-
ization unit was individual schoolchildren, showed increased SPT
reactivity after one year of albendazole treatment, but consistent
Figure 1. Trial Profile. HH: Household. Lost to follow up implies that the participants have no data from this time point onward. Temporarily
absent implies that the participants have no data at this time point but have data available at other time point.
doi:10.1371/journal.pone.0057899.g001
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with the Ecuadorean study, clinical allergy did not change
significantly.[11] It has been suggested that anthelminthic
treatment of longer duration might be needed to reveal the
modulatory effect of helminths.[12,13]
In the light of global deworming initiatives, it is important to
assess the effectiveness of and to monitor the risks associated with
anthelminthic treatment regiments. There is as yet no report of a
household-based cluster-randomized double-blind placebo-con-
trolled trial of repeated anthelminthic administration in a
community that would be expected to more effectively reduce
transmission of STH by decreasing household cross-contamina-
tion.
In an area where STH and malaria are co-endemic on Flores
Island, Indonesia, we conducted a household cluster-randomized
trial of three-monthly albendazole treatment over a two year study
period in a whole community to assess benefits and risks associated
with this anthelmintic treatment. Specifically we assessed its
impact on STH, malarial parasitemia and allergy.
Methods
Study population and design
This trial was conducted in two villages in the Ende District of
Flores Island, Indonesia (Appendix S1, p2) as described in detail
elsewhere.[14,15] The treatment was based on household and
given to all household members except those less than two years
old or pregnant (the Indonesian national program guideline).
Directly observed treatment was given three monthly during the
trial period (June 2008 to July 2010, with treatment starting in
Sept 2008). The primary outcomes were prevalence of malarial
parasitemia and SPT reactivity to allergens. Additional outcomes
were treatment effect on STH and BMI as well as malaria-like and
allergy symptoms.
We measured malaria outcomes in Nangapanda only. Malaria
was not endemic in Anaranda. Artemisinin-combination therapy
(ACT) treatment and treated bed net distribution were not
implemented during our study period.[16,17]
Allergy outcomes were measured, in both villages, in school-age
children (5–15 years old) as this group is particularly at risk of
developing allergy and asthma[18] and is the target population of
global deworming programs.
The study was approved by the Ethical Committee of the
Medical Faculty, University of Indonesia (ethical clearance ref:
194/PT02.FK/Etik/2006) and filed by the Committee of Medical
Ethics of the Leiden University Medical Center. The trial was
registered as clinical trial (Ref: ISRCTN83830814). Prior to the
study, written informed consent was obtained from participants or
from parents/guardians of children. The study is reported in
accordance with the CONSORT guidelines for cluster-random-
ized studies. The protocol for this trial and supporting CON-
SORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Randomization and masking
The population was randomized by IA using computer aided
block randomization at household level utilising Random Alloca-
tion software to receive albendazole (single dose of 400 mg) or a
matching placebo (both tablets from PT Indofarma Pharmaceu-
tical, Bandung, Indonesia). The treatment code was concealed
from trial investigators and participants. The un-blinding of
treatment codes occurred after all laboratory results had been
entered into the database (August 2011).
Procedures
Trained community workers measured fever, administered
monthly malaria-like symptoms questionnaire which was based
on WHO definitions[19] and took finger-prick blood for the three-
monthly malarial parasitemia survey. Subjects with fever
($37.5uC) or additional malaria-like symptoms (headache, fatigue
and nausea) at the time of visits were referred to the local primary
health centre (puskesmas). Thick and thin Giemsa-stained blood
smears were read at University of Indonesia. At baseline, 9 months
and 21 months after the first round of treatment blood was
collected for PCR-based detection of Plasmodium spp. (Appendix S1,
p2), a method that is more sensitive than microscopy.[20]
Regarding allergy outcomes, skin prick tests (SPT) with
allergens were performed on school-age children in Nangapanda
and Anaranda and clinical symptoms of allergy were recorded.
House dust mite (Dermatophagoides pteronyssinus and D. farinae; kindly
provided by Paul van Rijn from HAL Allergy Laboratories,
Leiden, The Netherlands) and cockroach (Blatella germanica;
Lofarma, Milan, Italy) were used for SPT which was considered
positive with 3 mm cut off.[14] The SPT was performed by one
investigator. IgE with specificity for aeroallergens (D. pteronyssinus
Table 1. Baseline characteristics.
N Placebo N Albendazole
Age (mean in years, SD) 2022 25.7 (18.7) 1982 25.8 (18.7)
Sex (female, n, %) 2022 1090 (53.9) 1982 1042 (52.6)
Area (rural, n, %) 2022 260 (12.9) 1982 253 (12.8)
BMI .19 years old (mean, SD) 575 22.3 (4.0) 582 21.8 (3.6)
Z score of BMI # 19 years old
(mean, SD)
427 21.20 (1.2) 386 21.37 (1.3)
Parasite infection (n, %)
Helminth (any spp) 655 571 (87.2) 609 533 (87.5)
Hookworm1 683 509 (74.5) 629 486 (77.3)
N. americanus1 683 503 (73.7) 629 481 (76.5)
A. duodenale1 683 44 (6.4) 629 41 (6.5)
A. lumbricoides1 683 238 (34.9) 629 209 (33.2)
S. stercoralis1 683 7 (1.0) 629 18 (2.9)
T. trichiura2 953 258 (27.1) 852 237 (27.8)
Malarial parasitemia (any spp)2 1225 60 (4.9) 1187 52 (4.4)
P. falciparum 1225 32 (2.6) 1187 28 (2.4)
P. vivax 1225 26 (2.1) 1187 18 (1.5)
P. malariae 1225 2 (0.2) 1187 7 (0.6)
Malarial parasitemia (any spp)1 772 195 (25.3) 739 200 (27.1)
P. falciparum 772 106 (13.7) 739 112 (15.2)
P. vivax 772 102 (13.2) 739 93 (12.6)
P. malariae 772 10 (1.3) 739 18 (2.4)
Skin prick reactivity (n, %)
Any allergen 711 190 (26.7) 653 163 (25.0)
House dust mite 711 88 (12.4) 653 75 (11.5)
Cockroach 711 163 (22.9) 653 140 (21.4)
Specific IgE, kU/L (median, IQR)
House dust mite 452 0.8 (0.3–2.6) 431 0.8 (0.2–2.4)
Cockroach 452 1.5 (0.4–5.7) 431 1.9 (0.5–5.0)
1diagnosed by PCR; 2diagnosed by microscopy.
The number of positives (n) of the total population examined (N).
doi:10.1371/journal.pone.0057899.t001
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and B. germanica) was measured in plasma using an ImmunoCAP
250 system (Phadia, Uppsala, Sweden) following the manufactur-
er’s instructions. All measurements were conducted in one
laboratory in the Netherlands. Symptoms of asthma and atopic
dermatitis were recorded using a modified visually-assisted version
of the International Study of Asthma and Allergy in Childhood
(ISAAC) questionnaire as reported before.[14]
Yearly stool samples were collected on a voluntary basis.
Trichuris was detected by microscopy and a multiplex real-time
PCR was used for detection of hookworms (Ancylostoma duodenale,
Necator americanus), Ascaris lumbricoides, and Strongyloides stercoralis
DNA as detailed before[15] (Appendix S1, p2). Very few subjects
were infected with S. stercoralis and therefore this infection was not
included in analyses.
Body weight and height were measured using the National
Heart Lung and Blood Institute practical guidelines (scale and
microtoise from SECA GmBH & Co, Hamburg, Germany).
Power calculation
Sample size estimation was based on the expected change in
primary outcomes taking into account a power of 90% and a
significance level of ,0.05 with a loss to follow-up of 20%. Based
on previous observations we expected to find a decrease in
malarial parasitemia prevalence and an increase in SPT reactivity
after anthelminthic treatment. Based on a prevalence of about
10% and a risk ratio (RR) of 0.60 we aimed to include 2412 people
in the malaria assessments. In a pilot study we found SPT to D.
pteronyssinus to be around 15%, and expected that due to treatment
the prevalence would increase. In order to find a RR of 1.5 we
aimed to include at least 1418 children.
Statistical analyses
For children #19 years, BMI age-standardized z-scores were
calculated according to WHO references.[21] The IgE data were
log-transformed to obtain normally distributed variable. To assess
treatment effects generalized linear mixed models were used which
provide a flexible and powerful tool to derive valid inference while
Figure 2. A) Percentage of helminth infected subjects in placebo and albendazole treatment arms. The presence of hookworms (by
PCR), Ascaris lumbricoides (by PCR) and Trichuris trichiura (by microscopy) or any of these helminth infections in subjects who provided stool samples
at baseline, 9 and 21 months post treatment (numbers are given in table S1A in Appendix S1). B) Effect of albendazole treatment on reduction
in the intensity as well as percentage of subjects positive for hookworm and Ascaris infection as determined by PCR. Negative is when
no helminth specific DNA was found. Positive Ct- values were grouped into three categories: Ct,30.0, 30.0#Ct,35.0 and$35.0 representing a high,
moderate and low DNA load, respectively.
doi:10.1371/journal.pone.0057899.g002
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capturing the data correlations induced by clustering within
households and repeated evaluations in time of the same subject.
Parameter estimates for treatment effects at 9 and 21 months and
95% confidence intervals are reported. The reported p-values are
obtained using likelihood ratio tests by comparing the model with
and without the treatment effect. Unless stated otherwise all
outcomes were adjusted for area (the two study villages in Ende
District: Nangapanda or Anaranda) as covariate in the model. For
the continuous outcomes (linear mixed-effects models[22] were
used with three random effects, namely to model clustering within
households a random household specific intercept was used and to
model correlation within subjects a random subject specific
intercept and slope were used. For the binary outcomes a logistic
model was used with random household effects and random
subject effects. All models were fitted using the lme4 package
(Appendix S1, p6-7).[23] For each fever and additional malaria-
like symptoms, total number of events and person months are
computed for each treatment arm. Hazard ratios for effect of
treatment were calculated with Cox regression with robust SE to
allow for within-household clustering (STATA 11).
Results
At baseline, 954 households with 4004 subjects were registered.
Randomization of households resulted in 1982 people assigned to
albendazole treatment and 2022 people to placebo (473 and 481
houses respectively). At baseline 87?3% of the individuals were
infected with one or more helminth species. The baseline
Figure 3. Effect of albendazole treatment on malarial parasitemia based on two age categories. Malarial parasitemia A) #15 and B) .15
years of age. The risk of malarial parasitemia after albendazole treatment compared to placebo is shown as odds ratio with 95% CI. The reference line
is set at 1, indicating that symbols at the right of this line represent an increased risk, while symbols at the left of the line would predict decreased risk
of malarial parasitemia. Note: at 9 month time point in those .15 years of age, the OR is ‘.
doi:10.1371/journal.pone.0057899.g003
Table 2. Effect of three-monthly albendazole treatment on malaria outcomes: Percentage of subjects with malarial parasitemia.
P. falciparum P. vivax P. malariae
Placebo Albendazole Placebo Albendazole Placebo Albendazole
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
Malarial parasitemia by microscopy
0 month 32/1225 (2.6) 28/1187 (2.4) 26/1225 (2.1) 18/1187 (1.5) 2/1225 (0.2) 7/1187 (0.6)
3 months 41/897 (4.6) 46/910 (5.1) 17/897 (1.9) 22/910 (2.4) 1/897 (0.1) 6/910 (0.7)
6 months 8/815 (1.0) 20/794 (2.5) 4/815 (0.5) 9/794 (1.1) 0 0
9 months 14/947 (1.5) 7/950 (0.7) 4/947 (0.4) 5/950 (0.5) 1/947 (0.1) 1/950 (0.1)
12 months 9/834 (1.1) 9/813 (1.1) 4/834 (0.5) 2/813 (0.2) 0 0
15 months 14/773 (1.8) 13/772 (1.7) 3/773 (0.4) 4/772 (0.5) 1/773 (0.1) 3/772 (0.4)
18 months 3/815 (0.4) 10/803 (1.2) 1/815 (0.1) 1/803 (0.1) 1/815 (0.1) 1/803 (0.1)
21 months 6/824 (0.7) 11/824 (1.3) 6/824 (0.7) 0 3/824 (0.4) 1/824 (0.1)
Malarial parasitemia by PCR
0 month 106/772 (13.7) 112/739 (15.2) 102/772 (13.2) 93/739 (12.6) 10/772 (1.3) 18/739 (2.4)
9 months 35/656 (5.3) 56/627 (8.9) 56/656 (8.5) 50/627 (8.0) 7/656 (1.1) 9/627 (1.4)
21 months 21/584 (3.6) 31/553 (5.6) 24/584 (4.1) 27/553 (4.9) 10/584 (1.7) 5/553 (0.9)
The number of positives (n) of the total population examined (N).
doi:10.1371/journal.pone.0057899.t002
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characteristics were similar between the treatment arms (table 1).
The overall trial profile is shown in figure 1, and figure S1A, S1B,
S1C (p13–15) in Appendix S1 separately for malaria, allergy and
helminth outcomes. The analysis was intention-to-treat and
involved all participants as assigned randomly at the start of the
trial. During the study, in the albendazole arm 61 people moved to
a house that was assigned to placebo while in the placebo arm 62
people moved to a house that was assigned to albendazole. The 44
subjects who died during the trial, included 4 people below the age
of 20, 3 between 20 and 40 and the rest above 40 years of age, and
were equally distributed between the treatment arms. At 9 months
post-treatment full compliance was 77.8% for albendazole
treatment and 78.0% for placebo. This was 63.1% and 62.5%
respectively at 21 months.
This intensive treatment with albendazole resulted in a
reduction but not elimination of STH. There was a decrease
both after 9 (OR (95% CI) = 0.07 (0.04–0.11) and 21 months (0.05
(0.03–0.08)) of treatment (p,0.0001). Albendazole had the largest
effect on hookworm followed by Ascaris while the effect on Trichuris
was less pronounced (figure 2A and table S1 in Appendix S1 p8).
Treatment also led to statistically significant reduction in the
intensity of hookworm and Ascaris infection as determined by PCR
(figure 2B). The fact that the stool sampling was on a voluntary
basis could have created a selection bias. Analyzing baseline
characteristics of subjects providing stool samples and those who
did not at 9 months follow up, showed no differences in helminth
prevalence, age and sex. Although at 21 months post treatment,
sex and helminth prevalence were not different, age was slightly
but significantly higher in subjects who provided stool samples
mean age in years (SD) = 29.9 (20.4) vs 24.3 (17.5), p = 0.006)
The overall percentage of subjects with malarial parasitemia,
irrespective of treatment arm, decreased over the trial period
(table 2). However, when the data were modelled to assess the
effect of albendazole treatment over time, there was a significant
(P = 0.0064) increase, which might result from the transient four-
fold increased risk of malarial parasitemia (OR 4.16 (1.35–12.80))
(table 3) at 6 months after initiation of treatment (after 2 doses of
albendazole). The effect of anthelminthic treatment was assessed
in those younger than 15 years of age who would be the prime
target of the global deworming programs. The transient increase
in parasitemia was only seen in the older (.15 years) age group
(figure 3). Malarial parasites were also assessed by PCR, at 9 and
21 months after initiation of treatment and revealed that
albendazole had no effect when all Plasmodium species were
considered together, but when analyzed separately there was a
significant increase in the percentage of subjects positive for P.
falciparum at 9 months post-treatment (table 4). There was no
difference in the incidence of fever and additional malaria-like
symptoms between the two treatment arms (table S2 in Appendix
S1 p10).
The proportion of subjects with SPT reactivity was 353/1364
(25.9%) at baseline. Albendazole treatment had no statistically
significant effect on SPT to any allergen (table 5), but it was noted
that there was an incremental increase in the risk of being SPT
positive to any allergen at 9 months and 21 months post initiation
of treatment. Moreover, additional analysis on allergens separate-
ly, showed a significantly higher SPT to cockroach at 21 months
after treatment (1.63 (1.07–2.50)) (table 6). The levels of IgE to
allergens showed that albendazole treatment had no effect (table 6).
No effect of treatment was seen on symptoms of asthma or atopic
dermatitis (table S3 in Appendix S1 p11).
No significant change in BMI was observed in children or in
adults (table S4 in Appendix S1 p12). Moreover, there was no
adverse effect of treatment reported.
Discussion
This household-based clustered-randomized, double-blind, pla-
cebo-controlled trial shows that administering a total of seven
single doses of albendazole, at three-monthly intervals, to a
population living in an area of Indonesia where STH are highly
prevalent, leads to decreased prevalence of helminth infections
which although statistically significant, can be taken as an
incomplete reduction. The results show a transient increase in
Table 3. Effect of three-monthly albendazole treatment on
malaria outcomes: Malarial parasitemia by microscopy
Placebo Albendazole OR (95%CI) *
n/N (%) n/N (%)
Malarial parasitemia (any
spp)
3 months 59/897 (6.6) 72/910 (7.9) 1.54 (0.75–3.16)
6 months 12/815 (1.5) 29/794 (3.7) 4.16 (1.35–12.80)
9 months 19/947 (2.0) 13/950 (1.4) 0.57 (0.16–2.04)
12 months 13/834 (1.6) 10/813 (1.2) 0.62 (0.12–3.15)
15 months 18/773 (2.3) 20/772 (2.6) 1.17 (0.18–7.65)
18 months 5/815 (0.6) 12/803 (1.5) 1.84 (0.12–29.03)
21 months 15/824 (1.8) 12/824 (1.5) 0.26 (0.01–6.59)
The number of positives (n) of the total population examined (N). *Odds ratio
and 95% confidence interval are based on mixed effects logistic regression
models. OR’s and 95% CI are shown for the separate time points on malarial
parasitemia. The p-value is generated from the modeled data for the combined
effect of albendazole treatment over time, which is significant (P = 0.0064) and
might result from the effect of 6 months post treatment time point.
doi:10.1371/journal.pone.0057899.t003
Table 4. Effect of three-monthly albendazole treatment on
malaria outcomes: Malarial parasitemia by PCR.
Placebo Albendazole OR (95% CI)
n/N (%) n/N (%)
Malaria (any spp)
9 months 95/656 (14.5) 103/627 (16.4) 1.13 (0.77–1.64)
21 months 53/584 (9.1) 59/553 (10.7) 1.09 (0.68–1.76)
P. falciparum
9 months 35/656 (5.3) 56/627 (8.9) 2.82 (1.29–6.15)
21 months 21/584 (3.6) 31/553 (5.6) 1.63 (0.63–4.22)
P. vivax
9 months 56/656 (8.5) 50/627 (8.0) 0.84 (0.41–1.71)
21 months 24/584 (4.1) 27/553 (4.9) 1.40 (0.56–3.52)
P. malariae
9 months 7/656 (1.1) 9/627 (1.4) 0.34 (0.04–2.79)
21 months 10/584 (1.7) 5/553 (0.9) 0.04 (0.00–0.39)
The number of positives (n) of the total population examined (N). Odds ratio
and 95% confidence interval based on logistic mixed models. The statistically
significant results are given in bold. The p-values are generated from the
modeled data for the combined effect of albendazole treatment over time for
each of the species separately, which were significant for P. falciparum
(P = 0.029) and P. malariae (P = 0.016).
doi:10.1371/journal.pone.0057899.t004
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malarial parasitemia in the albendazole- compared with the
placebo-treated arm in the first six months after initiation of
treatment. Albendazole treatment had no statistically significant
effect on the designated co-primary outcome, skin prick test
reactivity to allergens.
The clinical data collected of fever and additional malaria-like
symptoms, were not affected by the deworming. Clinical signs of
asthma and atopic dermatitis were also not affected by albendazole
treatment.
The prevalence of infection was high (.60%), which reflects the
situation in many areas that are being targeted by the global
deworming programs. Using a three-monthly treatment regimen
which represents an extreme scenario for helminth control
strategy, percentage of subjects positive for STH was reduced by
39% compared to placebo. It should be noted that in our study the
sensitive PCR method has been used. The reduction in the
proportion of subjects infected with hookworm and Ascaris was
more pronounced than for Trichuris infections, confirming the
findings using a single dose of albendazole.[24] Subjects who
provided stool samples at 21 months were slightly but significantly
older than those who did not. Given that hookworm infection is
more prevalent in older subjects, this may have contributed to the
poor deworming achieved by albendazole. The reduction achieved
in worm loads, did not have any beneficial effect on BMI.
Observational studies have reported that helminth infections affect
growth; however randomized trials have not been consis-
tent.[25,26] In this regard, our study would support the outcome
of a recent Cochrane review of no beneficial effect of deworming
programs on nutritional indicators [27] even though it can be
argued that in our study the suboptimal reduction in the STH
would not allow any beneficial effect of anthelmintic in terms of
BMI to be seen in the community. Importantly, the fact that the
effect of such an intensive deworming strategy in a community is
incomplete, needs to be considered in the agenda for the control
and elimination of helminth diseases of humans.[28]
Most studies on the effect of helminth infections on malarial
parasitemia and clinical malaria episodes have used cross-sectional
designs and have been inconclusive.[6] Longitudinal studies of
anthelminthic treatment have also reported conflicting re-
sults.[29,30] A small study conducted in Madagascar[29] has
reported an increase in malarial parasitemia in levimasole treated
subjects, older than 5 years of age, while in Nigeria [30],
albendazole treatment of pre school children was associated with
lower P. falciparum infection and anemia, however, the lost to
follow up in this study was very high. The question whether
albendazole treatment during pregnancy could affect health
outcomes in the offspring, was addressed in a recent report from
Uganda.[31] It was found that the incidence of malaria up to one
years of age was not different in the offspring of mothers born to
those treated with albendazole or placebo. Our study, reports the
results of a community wide randomized-controlled trial that used
three-monthly malarial parasitemia data obtained by microscopy.
A significantly higher percentage of subjects positive for malarial
parasites in the albendazole compared to the placebo arm was
seen but this seemed to be a transient effect and restricted to
individuals older than 15 years of age, an age group that is not the
main target of the current deworming programs. The question
Table 5. Effect of three-monthly albendazole treatment on
allergy outcomes: Skin prick test to any allergens.
Placebo Albendazole OR (95%CI) *
n/N (%) n/N (%)
SPT to any allergen
9 months 80/462 (17.3) 82/454 (18.1) 1.18 (0.74–1.86)
21 months 145/455 (31.9) 161/439 (36.7) 1.37 (0.93–2.01)
The number of positives (n) of the total population examined (N). *Odds ratio
and 95% confidence interval are based on mixed effects logistic regression
models. OR’s and 95% CI are shown for the separate time points on SPT to any
allergen. The p-value is generated from the modeled data for the effect of
albendazole treatment overtime and no significant effects were found (P.0.05).
doi:10.1371/journal.pone.0057899.t005
Table 6. Effect of three-monthly albendazole treatment on allergy outcomes: Skin prick test and specific IgE to aeroallergens.
Placebo Albendazole
Skin prick test reactivity* n/N (%) n/N (%) OR (95% CI)
House dust mite
9 months 36/462 (7.8) 35/454 (7.7) 1.31 (0.52–3.27)
21 months 77/455 (16.9) 76/439 (17.3) 1.37 (0.62–3.02)
Cockroach
9 months 60/462 (13.0) 65/454 (14.3) 1.27 (0.75–2.15)
21 months 112/455 (24.6) 139/439 (31.7) 1.63 (1.07–2.50)
Specific IgE** N (Median, IQR) N (Median, IQR) b (95% CI)
House dust mite
9 months 391 (0.46, 0.16–2.35) 381 (0.46, 0.14–1.98) 1.01 (0.91–1.12)
21 months 339 (0.82, 0.27–3.29) 334 (0.65, 0.20–2.69) 0.93 (0.81–1.06)
Cockroach
9 months 391 (1.47, 0.30–5.01) 381 (1.55, 0.44–4.40) 1.04 (0.93–1.16)
21 months 339 (1.83, 0.47–5.44) 334 (1.64, 0.42–4.82) 0.98 (0.85–1.14)
The number of positives (n) of the total population examined (N). *Odds ratio and 95% confidence interval based on logistic mixed models; **b (beta) and 95%
confidence interval based on generalized linear mixed models from the log-transformed IgE. The values shown are back-transformed. The p-values are generated from
the modeled data for the effect of albendazole treatment overtime and no significant effects were found (P.0.05).
doi:10.1371/journal.pone.0057899.t006
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arises as to why this effect was only seen in those .15 years of age.
This could be due to the fact that Ascaris infection is lower in older
age and therefore more easily cleared. It has been suggested that
Ascaris is the spesies of helminth that has the most effect on
malarial parasitemia and diseases.[6] Therefore by removing
Ascaris in older age, we might be seeing a more profound effect on
malarial parasitemia.
Using PCR, which enables detection of sub-microscopic
infections at species level, it was also concluded that albendazole
did not affect overall malarial parasitemia. When malaria species
were analyzed separately, the percentage of subjects infected with
P. falciparum but not with P. vivax increased significantly in the first
9 months post-treatment in the albendazole-treated arm, which is
contrary to our hypothesis that anthelminthic treatment would
reduce prevalence of malarial parasitemia.[32] It was expected
that by decreasing STH, the immune hyporesponsiveness would
be reversed and this would be associated with stronger immune
effector responses to malaria parasites. One of the possible
explanations for the enhanced malarial parasitemia would be that
with a reduction in STH, there is increased nutrient availability for
other co infections and their growth.
It has been suggested that there are different malaria outcomes
with different species of helminths; Ascaris being associated with
protection regarding parasitemia and severity of malaria while
hookworm with higher incidence of malaria.[6] Our study was not
powered to conduct a stratified analysis, and with the overall
gradual decrease in malaria in the study area during our study, the
numbers of subjects positive for malaria parasites are too few for
an ad hoc analysis.
The findings concerning allergy outcomes, although not
significant, are in line with our hypothesis that anthelminthic
treatment would increase SPT reactivity. The risk of SPT
reactivity increased incrementally with longer treatment and raises
the question whether even longer deworming periods are needed
for more pronounced effects on allergic outcomes. In support of
this, a recent study reported that 15–17 years of ivermectin
treatment for onchocerciasis control in Ecuador led to a significant
increase in SPT reactivity to allergens.[12] In the same country,
one year of anthelmintic treatment in schoolchildren did not lead
to any change in SPT.[10] The question whether different species
of helminths might affect allergic outcomes to a different degree,
remains unanswered. It is interesting that a one year anthelmintic
treatment in Vietnam where hookworm infection was the
prominent species, as in our study, resulted in a significant
increase in SPT positivity in schoolchildren. This is in contrast to
what was seen in Ecuador where Ascaris lumbricoides was the most
prevalent species. One common feature of the anthelmintic trials
seems to be that clinical symptoms of allergy do not change with
deworming. However, an important trial in pregnant women in
Uganda has shown an increased risk of infantile eczema in infants
of mothers treated with anthelminthics compared to those that
received placebo.[33] This could indicate that exposure to worms
in early life, might affect allergic outcomes more profoundly than
when helminths are removed later in life.[34]
One of the limitations of this trial is the overall decrease in
malarial parasitemia during the two year study period, most
probably caused by actively referring subjects with malaria-like
symptoms to puskesmas. Therefore further studies in areas highly
endemic for malaria are needed. Treatment in the trial did result
in a significant reduction in percentage of subjects infected with
STH, but this reduction was incomplete. It is therefore possible
that the community was insufficiently dewormed. However, our
primary aim was to measure the possible effect of deworming
programmes on malaria or allergy. We conclude that despite
transient increase in malarial parasitemia as a result of albendazole
treatment, there were no clinically relevant changes to outcome
measures 21 months after treatment was initiated.
In conclusion, an extremely intensive anthelminthic treatment
in a community where STH are highly endemic, does not lead to
elimination but reduces both prevalence and intensity of
helminths. Such MDA regiment appears safe and does not lead
to any significant change with respect to malaria infections or
allergies. However, it is worrying that such vigorous community
treatment does not have a more pronounced effect on STH
burden. Better integrated control strategies would be needed to
deworm and subsequently assess whether the risk for malaria
infections or allergies change.
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